|
1
|
Lam EW-F, Brosens JJ, Gomes AR and Koo
C-Y: Forkhead box proteins: Tuning forks for transcriptional
harmony. Nat Rev Cancer. 13:482–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Laoukili J, Kooistra MRH, Brás A, Kauw J,
Kerkhoven RM, Morrison A, Clevers H and Medema RH: FoxM1 is
required for execution of the mitotic programme and chromosome
stability. Nat Cell Biol. 7:126–136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laoukili J, Alvarez M, Meijer LA, Stahl M,
Mohammed S, Kleij L, Heck AJ and Medema RH: Activation of FoxM1
during G2 requires cyclin A/Cdk-dependent relief of autorepression
by the FoxM1 N-terminal domain. Mol Cell Biol. 28:3076–3087. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang I-C, Chen Y-J, Hughes D, Petrovic V,
Major ML, Park HJ, Tan Y, Ackerson T and Costa RH: Forkhead box M1
regulates the transcriptional network of genes essential for
mitotic progression and genes encoding the SCF (Skp2-Cks1)
ubiquitin ligase. Mol Cell Biol. 25:10875–10894. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gemenetzidis E, Elena-Costea D, Parkinson
EK, Waseem A, Wan H and Teh M-T: Induction of human epithelial
stem/progenitor expansion by FOXM1. Cancer Res. 70:9515–9526. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huynh KM, Soh J-W, Dash R, Sarkar D,
Fisher PB and Kang D: FOXM1 expression mediates growth suppression
during terminal differentiation of HO-1 human metastatic melanoma
cells. J Cell Physiol. 226:194–204. 2011. View Article : Google Scholar
|
|
7
|
Wang Z, Park HJ, Carr JR, Chen YJ, Zheng
Y, Li J, Tyner AL, Costa RH, Bagchi S and Raychaudhuri P: FoxM1 in
tumorigenicity of the neuroblastoma cells and renewal of the neural
progenitors. Cancer Res. 71:4292–4302. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Monteiro LJ, Khongkow P, Kongsema M,
Morris JR, Man C, Weekes D, Koo CY, Gomes AR, Pinto PH, Varghese V,
et al: The Forkhead Box M1 protein regulates BRIP1 expression and
DNA damage repair in epirubicin treatment. Oncogene. 32:4634–4645.
2013. View Article : Google Scholar
|
|
9
|
Khongkow P, Karunarathna U, Khongkow M,
Gong C, Gomes AR, Yagüe E, Monteiro LJ, Kongsema M, Zona S, Man EP,
et al: FOXM1 targets NBS1 to regulate DNA damage-induced senescence
and epirubicin resistance. Oncogene. 33:4144–4155. 2014. View Article : Google Scholar :
|
|
10
|
Li X, Qiu W, Liu B, Yao R, Liu S, Yao Y
and Liang J: Forkhead box transcription factor 1 expression in
gastric cancer: FOXM1 is a poor prognostic factor and mediates
resistance to docetaxel. J Transl Med. 11:2042013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chu X-Y, Zhu Z-M, Chen L-B, Wang JH, Su
QS, Yang JR, Lin Y, Xue LJ, Liu XB and Mo XB: FOXM1 expression
correlates with tumor invasion and a poor prognosis of colorectal
cancer. Acta Histochem. 114:755–762. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Martin KJ, Patrick DR, Bissell MJ and
Fournier MV: Prognostic breast cancer signature identified from 3D
culture model accurately predicts clinical outcome across
independent datasets. PLoS One. 3:e29942008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bektas N, Haaf A, Veeck J, Wild PJ,
Lüscher-Firzlaff J, Hartmann A, Knüchel R and Dahl E: Tight
correlation between expression of the Forkhead transcription factor
FOXM1 and HER2 in human breast cancer. BMC Cancer. 8:422008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xia L, Huang W, Tian D, Zhu H, Zhang Y, Hu
H, Fan D, Nie Y and Wu K: Upregulated FoxM1 expression induced by
hepatitis B virus X protein promotes tumor metastasis and indicates
poor prognosis in hepatitis B virus-related hepatocellular
carcinoma. J Hepatol. 57:600–612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu M, Dai B, Kang S-H, Ban K, Huang FJ,
Lang FF, Aldape KD, Xie TX, Pelloski CE, Xie K, et al: FoxM1B is
overexpressed in human glioblastomas and critically regulates the
tumorigenicity of glioma cells. Cancer Res. 66:3593–3602. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakamura S, Hirano I, Okinaka K, Takemura
T, Yokota D, Ono T, Shigeno K, Shibata K, Fujisawa S and Ohnishi K:
The FOXM1 transcriptional factor promotes the proliferation of
leukemia cells through modulation of cell cycle progression in
acute myeloid leukemia. Carcinogenesis. 31:2012–2021. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z, Zheng Y, Park HJ, Li J, Carr JR,
Chen YJ, Kiefer MM, Kopanja D, Bagchi S, Tyner AL, et al: Targeting
FoxM1 effectively retards p53-null lymphoma and sarcoma. Mol Cancer
Ther. 12:759–767. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Uddin S, Hussain AR, Ahmed M, Siddiqui K,
Al-Dayel F, Bavi P and Al-Kuraya KS: Overexpression of FoxM1 offers
a promising therapeutic target in diffuse large B-cell lymphoma.
Haematologica. 97:1092–1100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao B, Barrera LA, Ersing I, Willox B,
Schmidt SC, Greenfeld H, Zhou H, Mollo SB, Shi TT, Takasaki K, et
al: The NF-κB genomic landscape in lymphoblastoid B cells. Cell
Rep. 8:1595–1606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Buchner M, Park E, Geng H, Klemm L, Flach
J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, et al:
Identification of FOXM1 as a therapeutic target in B-cell lineage
acute lymphoblastic leukaemia. Nat Commun. 6:64712015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bhatla T, Wang J, Morrison DJ, Raetz EA,
Burke MJ, Brown P and Carroll WL: Epigenetic reprogramming reverses
the relapse-specific gene expression signature and restores
chemosensitivity in childhood B-lymphoblastic leukemia. Blood.
119:5201–5210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Accordi B, Galla L, Milani G, Curtarello
M, Serafin V, Lissandron V, Viola G, te Kronnie G, De Maria R,
Petricoin EF III, et al: AMPK inhibition enhances apoptosis in
MLL-rearranged pediatric B-acute lymphoblastic leukemia cells.
Leukemia. 27:1019–1027. 2013. View Article : Google Scholar
|
|
23
|
Hui RC-Y, Gomes AR, Constantinidou D,
Costa JR, Karadedou CT, Fernandez de Mattos S, Wymann MP, Brosens
JJ, Schulze A and Lam EW: The forkhead transcription factor FOXO3a
increases phosphoinositide-3 kinase/Akt activity in drug-resistant
leukemic cells through induction of PIK3CA expression. Mol Cell
Biol. 28:5886–5898. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bortolozzi R, Viola G, Porcù E, et al: A
novel copper (I) complex induces ER-stress-mediated apoptosis and
sensitizes B-acute lymphoblastic leukemia cells to chemotherapeutic
agents. Oncotarget. 5:5978–5991. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chou T-C: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nilsson I and Hoffmann I: Cell cycle
regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res.
4:107–114. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bertoli C, Skotheim JM and de Bruin RAM:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kwok JM-M, Myatt SS, Marson CM, Coombes
RC, Constantinidou D and Lam EW-F: Thiostrepton selectively targets
breast cancer cells through inhibition of forkhead box M1
expression. Mol Cancer Ther. 7:2022–2032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hegde NS, Sanders DA, Rodriguez R and
Balasubramanian S: The transcription factor FOXM1 is a cellular
target of the natural product thiostrepton. Nat Chem. 3:725–731.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Carrano AC, Eytan E, Hershko A and Pagano
M: SKP2 is required for ubiquitin-mediated degradation of the CDK
inhibitor p27. Nat Cell Biol. 1:193–199. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hara T, Kamura T and Nakayama K, Oshikawa
K, Hatakeyama S and Nakayama K: Degradation of p27(Kip1) at the
G(0)–G(1) transition mediated by a Skp2-independent ubiquitination
pathway. J Biol Chem. 276:48937–48943. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu Z and Hunter T: Ubiquitylation and
proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2)
CDK inhibitors. Cell Cycle. 9:2342–2352. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koo C-Y, Muir KW and Lam EW-F: FOXM1: From
cancer initiation to progression and treatment. Biochim Biophys
Acta. 1819.28–37. 2012.
|
